Printer Friendly
The Free Library
22,725,466 articles and books

DOBI Medical International Exhibits ComfortScan(R) System at CHINA-PHARM Conference.

MAHWAH, N.J. -- DOBI DOBI Division of Banking and Insurance  Medical International, Inc. (DBMI DBMI Department of BioMedical Informatics
DBMI Double-Basis Multiplicative Inverse
DBMI Data Base Marketing, Inc
DBMI Data Base Module for Informix
.OB), today announced that it will exhibit its Dynamic Optical Breast Imaging (DOBI(R)) technology, known as the ComfortScan(R) system, at the 10th China International Pharmaceutical Exhibition (CHINA-PHARM) from October 25-28 in Shanghai's New International Expo Centre, Shanghai, China (Booth A100, Hall E2). One of the leading exhibitions in the Asian pharmaceutical industry, CHINA-PHARM drew nearly 24,000 international visitors in 2004 and featured over 330 exhibitors from 27 countries. The event is supported by the Shanghai Food and Drug Administration.

DOBI Medical recently signed a ComfortScan system consulting agreement with the China Center for Pharmaceutical International Exchange (CCPIE) in Beijing, China, serving as another key step in the continued expansion of its international presence. Under the agreement terms, CCPIE is working with the SFDA SFDA State Food and Drug Administration (China)
SFDA Saudi Food & Drug Authority
, China's governmental agency having oversight over approval of medical devices, to conduct a clinical investigation of the ComfortScan system to aid in obtaining national approval. Last month, the ComfortScan system passed technical inspection, one of several requirements precedent to SFDA approval for medical devices in China.

The Chinese Anti-cancer Association estimates that more than 300 million women are at risk for breast cancer in China, making it one of the most common cancers among women in that nation. Breast cancer incidence has increased annually by at least 27% over the past decade, replacing lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell.  as the most rapidly growing cancer in China. In addition, the death rate from breast cancer has increased by 3% annually in recent years, making breast cancer the leading killer of Chinese women. In fact, the incidence in China's major cities has reached the level of western countries. According to according to
1. As stated or indicated by; on the authority of: according to historians.

2. In keeping with: according to instructions.

 reports, Chinese women between the ages of 40 and 49 fall into the highest risk age groups.

About DOBI Medical International, Inc.

DOBI Medical is a developmental stage, medical imaging company working to create a new means for the improved diagnosis of cancer through the detection of abnormal neovascularization ("angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization.

") associated with tumors. DOBI Medical International's first application of the technology is the ComfortScan system, a gentle, noninvasive, and nonionizing, optical imaging system designed as an adjunct to mammography mammography, diagnostic procedure that uses low-dose X rays to detect abnormalities in the breasts. The early diagnosis of breast cancer made possible by the routine use of mammography for screening women increases a woman's treatment alternatives and improves her  to assist physicians in the detection and management of breast cancer. The ComfortScan system is intended to achieve this by providing new, physiology-based imagery of abnormal vascularization vascularization /vas·cu·lar·iza·tion/ (vas?ku-ler-i-za´shun)
1. the process of becoming vascular.

2. angiogenesis.

3. the surgically induced development of vessels in a tissue.
 in the breast that is not readily available today. The ComfortScan system has CE Mark and UL certifications. DOBI Medical is a certified ISO (1) See ISO speed.

(2) (International Organization for Standardization, Geneva, Switzerland, An organization that sets international standards, founded in 1946. The U.S. member body is ANSI.
 9001:2000 and ISO 13485:2003 company. The Company currently sells its ComfortScan systems to international distributors for installation at international clinical trial sites. The ComfortScan system is not being sold in the U.S. as it is limited by U.S. law to investigational use until approved by the FDA FDA
Food and Drug Administration

FDA, See Food and Drug Administration.

FDA, the abbreviation for the Food and Drug Administration.
, which cannot be guaranteed. For more information on DOBI Medical International or the ComfortScan system, visit


A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.

Statements in this press release contain information that includes or is based upon certain "forward-looking statements" relating to relating to relate prepconcernant

relating to relate prepbezüglich +gen, mit Bezug auf +acc 
 our business. These forward-looking statements represent management's current judgments and assumptions as of the date of this report. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts, and are frequently accompanied by the use of such words as "may," "will," "anticipates," "plans," "believes," "expects," "projects," "intends," "seeks," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors, including without limitation, successful verification and validation Verification and Validation (V&V) is the process of checking that a product, service, or system meets specifications and that it fulfills its intended purpose. These are critical components of a quality management system such as ISO 9000.  for release of our ComfortScan 2.0 system; those relating to our ability to timely and successfully complete our patient clinical trials; our ability to timely and successfully complete and submit our premarket approval premarket approval Medical devices A scientific and regulatory review by the FDA to ensure the safety and effectiveness of a Class III device, before its approval for marketing. See Advisory panel, Medical device.  application to the FDA; the timely and final approval by the FDA of our ComfortScan system as a adjunct to mammography, which approval in the U.S. cannot be assured; the submission and final approval of our ComfortScan system in various international markets, which approval cannot be assured; the success and continued improvements in our product development and research efforts; our ability to timely meet U.S. and foreign government laws and industry standards; our ability to meet U.S. and foreign medical device quality regulation standards required to maintain our CE Mark, and to maintain our ISO, UL and FDA export certifications; our ability to timely and successfully ship and deliver our products into international markets; the acceptance and use of our ComfortScan system by physicians, hospitals, imaging clinics, and patients; and our ability to obtain adequate third party coverage, coding and reimbursement Reimbursement

Payment made to someone for out-of-pocket expenses has incurred.
 from U.S. and foreign government and private payers.

We caution readers not to place undue reliance on forward-looking statements, which speak only as of the date of this report. Any one of these or other risks, uncertainties, other factors or any inaccurate judgments and assumptions could cause actual results to be materially different from those described herein or elsewhere by us. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission, which we strongly urge you to read and consider, including the "Investment Considerations" and the "Cautionary Factors That May Affect Future Results" as set forth in our 2004 Annual Report on Form 10-KSB, as amended, and the "Risk Factors" in our Registration Statement, 2005 on Form SB-2 declared effective on May 11, 2005, our 2005 Second Quarter Report on Form 10-QSB, and our Current Reports on Form 8-K Form 8-K

The form required by the SEC when a publicly held company incurs any event that might affect its financial situation or the share value of its stock.

Form 8-K

See 8-K.
, all of which may be accessed from our website at Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above and elsewhere in our reports filed with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion




Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 25, 2005
Previous Launches to Provide Brokers a Valuable Online Resource for Life Settlements; Rumson Capital LP Introduces New Web Site to Educate...
Next Article:NorthSeas Introduces Enterprise E-mail Archiving Appliance During Storage Networking World.

Related Articles
D-Pharm Appoints Dr. Peter Lewis as Chairman of the Board.
D-Pharm Establishes Neuroscience Research Collaboration With Lilly.
Bergen Brunswig Announces New Agreement With Spartan Stores Acquisitions; New Supply Agreements Confirm Success of Initial Contract.
D-Pharm Ltd. Raises $30 Million in Private Financing.
D-Pharm Ltd. to Present at the Robertson Stephens Medical Conference.
D-Pharm Achieves First Milestone From Partner Shire Pharmaceuticals For its Proprietary Anti-Epileptic Agent SPD 421.
DOBI Medical International to Exhibit ComfortScan(R) System at the 2006 European Congress of Radiology.
DOBI Medical International Updates Progress in China And Announces Exhibit of ComfortScan(R) System at the 2006 CHINA MED.
DOBI Medical International to Exhibit ComfortScan(R) System at 2006 CHINA MED.
DOBI Medical International to Exhibit ComfortScan(R) System at the 2006 JPR Conference.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters